Voyager Therapeutics Inc Stock Price, News & Analysis

Voyager Therapeutics (Nasdaq: VYGR) reported Q2 2025 financial results and operational updates, highlighting significant progress in its neurotherapeutics pipeline. The company has extended its cash runway into 2028, with a current cash position of $262 million. Q2 2025 showed revenue of $5.2M and a net loss of $33.4M.

Key developments include the addition of a new APOE program to their Alzheimer's disease franchise, bringing their AD portfolio to four assets. The company maintains 11 partnered programs with potential milestone payments of $2.6B. Multiple clinical milestones are expected in 2026, including data readouts for VY7523 and the initiation of clinical trials for VY1706 and Neurocrine-partnered programs.

[ "Cash runway extended into 2028, providing stability through multiple clinical milestones", "Strong cash position of $262 million as of June 30, 2025", "Potential for $2.6B in development milestone payments from partnered programs", "Pipeline expansion with fourth Alzheimer's disease asset (APOE program)", "Multiple clinical programs advancing toward 2026 milestones" ]

Voyager Therapeutics (Nasdaq: VYGR) has expanded its Alzheimer's disease (AD) portfolio by introducing a new APOE-targeting gene therapy program. The program utilizes their proprietary TRACER capsid technology to deliver a bifunctional payload that reduces APOE4 expression (a high-risk variant) while delivering protective APOE2 variant.

This addition brings Voyager's AD franchise to four wholly-owned assets: VY7523 (anti-tau antibody in clinical trials), VY1706 (tau silencing gene therapy), a vectorized anti-Aβ antibody gene therapy, and the new APOE program. Preclinical studies showed significant APOE4 reduction in key brain regions with a single IV injection, while maintaining overall APOE levels through APOE2 expression.

Voyager Therapeutics (VYGR), a biotech company focused on genetic treatments for neurological diseases, announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. CEO Alfred W. Sandrock, Jr., M.D., Ph.D., along with other management team members, will be featured in a pre-recorded fireside chat. The presentation will be available as an on-demand webcast starting June 17, 2025, at 7:00 a.m. ET through the Investors section of Voyager's website. The webcast recording will remain accessible for a minimum of 30 days after the event.

Voyager Therapeutics (VYGR) has published groundbreaking research in Molecular Therapy demonstrating how alkaline phosphatase (ALPL) can transport novel AAV capsids across the blood-brain barrier (BBB). The company's novel capsid VCAP-102 showed 20- to 400-fold increased gene transfer across multiple brain regions compared to AAV9 in both rodents and non-human primates. In studies with next-generation CNS capsids, a single intravenous dose achieved remarkable neuron transduction rates: up to 98% of dopaminergic neurons in substantia nigra, 94% of motor neurons in the spinal cord, and 87-99% of astrocytes across brain regions. The company is advancing two gene therapy programs towards IND filings this year with a partner, while also developing stealth capsids with immune-evading capabilities and exploring non-viral CNS delivery approaches.

Voyager Therapeutics (VYGR) reported Q1 2025 financial results with a net loss of $31.0 million, compared to $11.3 million in Q1 2024. The company maintains a strong cash position of $295 million, providing runway into mid-2027. Key highlights include progress on their tau-targeting programs: VY1706 showed up to 73% knockdown of tau mRNA in CNS following a single IV dose, while VY7523's multiple ascending dose trial for Alzheimer's continues. Through their Neurocrine partnership, IND submissions are expected in 2025 for Friedreich's ataxia and GBA1 gene therapy programs, with potential milestone payments of $35 million in 2025-2026. Q1 collaboration revenue was $6.5 million, down from $19.5 million year-over-year. R&D expenses increased to $31.5 million from $27.1 million, while G&A expenses rose to $9.6 million from $8.6 million in the same period last year.

Voyager Therapeutics announced eight presentations at the upcoming American Society of Gene & Cell Therapy's (ASGCT) annual meeting in New Orleans, May 13-17, 2025. The company will showcase significant advances in gene therapy for neurological diseases.

Key highlights:

• VY1706, their tau silencing gene therapy, achieved up to 73% knockdown of tau mRNA in non-human primates after a single IV dose
• Their TRACER capsids demonstrated impressive results, with 43-98% neuron transduction and 87-99% astrocyte transduction across brain regions
• Presentations will cover anti-amyloid gene therapy and immune evasion developments

The company expects to file two Investigational New Drug (IND) applications this year and another next year. The presentations span multiple areas, including:

• Anti-tau and anti-amyloid therapies for Alzheimer's disease
• Reducing immunogenicity of capsids
• Enhancing manufacturing processes

Voyager Therapeutics (VYGR) has presented new preclinical data for its tau-targeting programs in Alzheimer's disease treatment at AD/PD™ 2025. The company's tau silencing gene therapy VY1706 demonstrated significant results in non-human primate studies, showing 44-73% reduction in tau mRNA and 27-55% reduction in tau protein levels after a single intravenous dose, with effects lasting up to three months.

The therapy achieved broad brain distribution while showing 30-fold liver de-targeting compared to wild type AAV9. VY1706 is advancing toward IND filing expected in 2026. Additionally, their anti-tau antibody VY7523 showed selectivity for pathologic tau tangles in preclinical studies. The company is currently conducting a multiple ascending dose trial of VY7523 in early Alzheimer's patients, with initial tau PET imaging data expected in second half of 2026.

Voyager Therapeutics (VYGR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its tau-targeting programs for Alzheimer's disease. The company's tau silencing gene therapy VY1706 showed promising results in NHP studies, with 50-73% reduction in tau mRNA levels across the cerebral cortex. Their anti-tau antibody VY7523 demonstrated positive safety and pharmacokinetic results in Phase 1 trials.

Financial highlights include:

• Q4 2024 collaboration revenue of $6.3M vs $90.1M in Q4 2023
• Full year 2024 revenue of $80M vs $250M in 2023
• Q4 2024 net loss of $34.5M vs net income of $56.4M in Q4 2023
• Cash position of $332.4M as of December 31, 2024

The company expects cash runway into mid-2027 and anticipates several key milestones, including IND filings for GBA1 Parkinson's therapies in 2025 and tau PET imaging data from VY7523 trials in H2 2026.

Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its fourth quarter 2024 financial results announcement for March 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.

The webcast will be accessible through the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay will be available at the same location approximately two hours after the call's completion and will remain accessible for at least 30 days.